Calls
2
u/MattieuOdd
Reddit r/ValueInvesting
Win Rate
50.0%
return
-10.2%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 12
$1076.55
+7.1%
The author argues oral GLP-1s like Eli Lilly's orfo will capture more than 25% of the total obesity market by 2030, contrary to analyst estimates. The author cites strong behavioral anchors such as fear of injection, pain, and the perception that injection therapy signals severe health problems, which should drive patients toward oral alternatives. The author acknowledges injectables may have better efficacy and lower side effects but believes oral benefits outweigh these factors.
GLP-1 / Obesity
Long
Jan 12
$59.73
-27.4%
The author argues oral GLP-1s like Novo Nordisk's sema will capture more than 25% of the total obesity market by 2030, contrary to analyst estimates. The author cites strong behavioral anchors such as fear of injection, pain, and the perception that injection therapy signals severe health problems, which should drive patients toward oral alternatives. The author acknowledges injectables may have better efficacy and lower side effects but believes oral benefits outweigh these factors.
GLP-1 / Obesity
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/MattieuOdd has 2 trade ideas tracked on Buzzberg across 2 tickers since January 2026. Most covered: NVO, LLY.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
